Dongrui Pharmaceutical (2348.HK): undervalued pharmaceutical companies have impressive returns per share
Dongrui Pharmaceutical (02348.HK): The pharmaceutical industry faces a slowdown in growth, and the company's business maintains high growth
Dongrui Pharmaceutical (2348.HK) Research Briefing: Raytech Drags Down Company Performance to Track New Product Progress
Dongrui Pharmaceutical (2348.HK) Research Briefing: Steady operations and long-term development are worth looking forward to
Dongrui Pharmaceutical (2348.HK) Research Briefing: Actual Operation Is Growing Rapidly, Lei Yi De's Adjustment Was Short
Dongrui Pharmaceutical (2348.HK): Short-term pain brought about by changes in sales models
Dongrui Pharmaceutical (2348.HK): Excellent specialty pharmaceutical company with steady growth and undervalued value
Dongrui Pharmaceutical (2348.HK) Research Briefing: Appropriate Business Strategy for Rapid Profit Growth
Dongrui Pharmaceutical (2348.HK) Annual Report Review: In line with market expectations, the growth rate of system specialty drugs has slowed somewhat, and the API business is recovering
Dongrui Pharmaceutical (2348.HK): Superior specialty drugs continue to drive the company's rapid development
BUSINESS UPDATE FROM DAWNRAYS (2348.HK)
Torui Pharmaceutical (2348.HK): Strong fundamentals
Dongrui Pharmaceutical (2348.HK): No worries about fundamentals
Dongrui Pharmaceuticals (2348:HK): Ansan Series and Raytech continue to be growth points to maintain buying
Dongrui Pharmaceutical (2348.HK): The performance is in line with expectations and the valuation is very attractive. Reiterates the purchase
Dongrui Pharmaceutical (2348.HK) Research Briefing: Performance Fully Meets Expectations
Dongrui Pharmaceutical (2348.HK): Changing the CEO will not change the company's strategic valuation is very attractive. Reiterating the purchase
Dongrui Pharmaceutical (2348.HK): Company research confirms strong growth, valuation is very attractive, and reaffirms purchase
Dongrui Pharmaceutical (2348.HK): Successful transformation into an excellent specialty pharmaceutical company with more definite and stable future growth
Dongrui Pharmaceutical (2348.HK): The API business bottomed out in 2013 to see the strength of specialty drugs
No Data